{"id":"gentamicin-narrow-spectrum-betalactam","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"2-5","effect":"Ototoxicity"},{"rate":"1-3","effect":"Allergic reaction (beta-lactam)"},{"rate":"5-10","effect":"Hypokalemia"},{"rate":"2-5","effect":"Nausea/vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gentamicin is an aminoglycoside that binds to bacterial ribosomes and inhibits protein synthesis, while the narrow-spectrum beta-lactam (such as a penicillin or cephalosporin) inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. This combination provides synergistic bactericidal activity, particularly effective against gram-negative aerobic bacteria and some gram-positive organisms, commonly used in empiric therapy for serious infections.","oneSentence":"Gentamicin and a narrow-spectrum beta-lactam antibiotic work synergistically to kill bacteria by inhibiting protein synthesis and disrupting cell wall integrity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:14.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-negative bacterial infections"},{"name":"Empiric therapy for hospital-acquired infections"},{"name":"Febrile neutropenia in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":"Sepsis","enrollment":1900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gentamicin + narrow spectrum betalactam","genericName":"Gentamicin + narrow spectrum betalactam","companyName":"University Hospital, Akershus","companyId":"university-hospital-akershus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gentamicin and a narrow-spectrum beta-lactam antibiotic work synergistically to kill bacteria by inhibiting protein synthesis and disrupting cell wall integrity. Used for Serious gram-negative bacterial infections, Empiric therapy for hospital-acquired infections, Febrile neutropenia in immunocompromised patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}